Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 +3.37%62 Operating Margin % is 36.12% as of Mar. 2026, which is 3548% above its 10-year median of 0.99. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円693.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 77.23% on this metric.
The historical rank and industry rank for Human Metabolome Technologies's Operating Margin % or its related term are showing as below:
TSE:6090'
s Operating Margin % Range Over the Past 10 Years
Min: -43.79 Med: 0.99 Max: 17.15
Current: 14.76
TSE:6090's Operating Margin % is ranked better than 77.23% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.985
vs TSE:6090: 14.76
Human Metabolome Technologies (TSE:6090) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Human Metabolome Technologies Operating Margin % Related Terms
Human Metabolome Technologies Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Operating Margin % Chart
TSE:6090 vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Operating Margin % falls into.
Human Metabolome Technologies Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Operating Margin % of 36.12% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Human Metabolome Technologies and its competitors. This is 3548% above median its historical median of 0.99. According to the industry distribution chart, Human Metabolome Technologies ranks #46 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 22.8%.
Is Human Metabolome Technologies' Operating Margin % too high?
Human Metabolome Technologies' current Operating Margin % of 36.12% is 3548% above median its 10-year median of 0.99. Based on the distribution chart, Human Metabolome Technologies ranks #46 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #46 out of 202 companies for Operating Margin %. This places Human Metabolome Technologies in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Operating Margin % is 36.12%, which is 3548% above median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円693.69, compared to a current price of 円645.00 — trading 7% below its estimated fair value. The current Operating Margin % is 36.12%, which is 3548% above median its 10-year median of 0.99. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Operating Margin % is 36.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円645.00 is trading 7% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
Operating Margin %: 36.12% (3548% above median its 10-year median of 0.99)
GF Value™: 円693.69 vs. price of 円645.00 (7% below fair value)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
